Safety Evaluation of Adverse Reactions in Diabetes

The SAFEGUARD project aims to assess and further quantify and understand the effects of all existing oral blood glucose lowering agents in humans by means of the analysis of anonymised and aggregated data from more than 1.7 million diabetes patients in Europe and the US, the revision of published observational studies and clinical trials, and the implementation of state-of-the-art mechanistic studies. SAFEGUARD is funded with 2.9 million Euro granted by the European Commission in the 7th Framework Programme, coordinated by Erasmus University Medical Center (Netherlands) and carried out by 14 leading research institutions and SMEs.
[separator size=’small’ margin=’small’/]
SAFEGUARD project flyer
SAFEGUARD project website
[separator size=’small’ margin=’small’/]